Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Physical Frailty Intervention for Older Adults With Hypertension and Physical Frailty (PFIM)

12. November 2026 aktualisiert von: Dong Yuan

Development and Evaluation of Physical Frailty Intervention Module for Older Adults With Hypertension in Shandong Province, China

Physical frailty is a common health concern among older adults with hypertension and may contribute to reduced physical function, loss of independence, and poorer quality of life. This study aims to evaluate the effectiveness of a 12-week nurse-led Physical Frailty Intervention Module (PFIM) among community-dwelling older adults with hypertension and physical frailty in Shandong Province, China.

This nonrandomized controlled study will recruit 124 participants aged 60 years or older from three primary healthcare institutions. Two institutions will be assigned to the intervention group, which will receive the PFIM in addition to usual care, while one institution will serve as the control group and provide usual care only.

The PFIM is based on the Health Action Process Approach (HAPA) and combines simplified Baduanjin exercise, basic nutrition guidance, hypertension self-management education, and behavioral support. The intervention includes nurse-led group sessions, individualized home-based exercise, and follow-up support over 12 weeks.

Physical frailty will be the primary outcome. Physical performance, nutritional status, health literacy, perceived social support, depressive symptoms, and quality of life will be assessed as secondary outcomes at baseline and after 12 weeks.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This study is the third phase of a multiphase research project involving the development, validation, and evaluation of a Physical Frailty Intervention Module (PFIM) for older adults with hypertension and physical frailty.

A pragmatic, two-arm, nonrandomized controlled quasi-experimental design will be used. The study will be conducted at three primary healthcare institutions in Yanzhou District, Jining, Shandong Province, China. Two institutions will be allocated to the intervention group and one to the control group to minimize contamination. The planned sample size is 124 participants, with 62 participants per group.

The 12-week PFIM is informed by the Health Action Process Approach (HAPA) and delivered by trained nurses. It comprises three stages:

Weeks 1-4 focus on motivation and participation preparation through weekly face-to-face group education sessions addressing physical frailty, hypertension, nutrition, exercise safety, and behavioral change.

Weeks 5-8 emphasize action planning and behavior initiation through weekly group sessions and home-based simplified Baduanjin practice two to three times weekly for 15-20 minutes per session.

Weeks 9-12 focus on behavior maintenance through continued home practice, progressing toward 20-30 minutes per session when appropriate, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11.

Standing or seated simplified Baduanjin exercises will be assigned according to participants' physical performance and clinical safety assessments. The control group will receive usual hypertension care without the structured PFIM.

The primary outcome is physical frailty severity, measured using the FRAIL Scale. Secondary outcomes include physical performance (SPPB), nutritional status (MNA-SF), health literacy (HLS-SF12), perceived social support (PSSS), depressive symptoms (GDS-15), and quality of life (OPQOL-brief). Outcomes will be assessed at baseline and immediately after the 12-week intervention.

Studientyp

Interventionell

Einschreibung (Geschätzt)

124

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Shandong
      • Jining, Shandong, China, 272100
        • Caohe Town Health Center
        • Kontakt:
      • Jining, Shandong, China, 272100
        • Jiuxianqiao Subdistrict Community Health Service Center
        • Kontakt:
      • Jining, Shandong, China, 272100
        • Yandian Central Health Center
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

60 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Aged 60 years or older.
  • Physician-diagnosed hypertension or current use of physician-prescribed antihypertensive medication.
  • Physical frailty, defined as a FRAIL Scale score of 3 or higher.
  • Community-dwelling and residing within the catchment area of one of the participating primary healthcare institutions.
  • Adequate cognitive and communication abilities to understand study procedures, communicate in Mandarin or the local dialect, complete questionnaires with or without assistance, and provide written informed consent.
  • Medically stable and considered fit for light-to-moderate physical activity by the treating physician.

Exclusion Criteria:

  • Major acute illness requiring hospitalization within the preceding three months, such as acute myocardial infarction, acute stroke, or acute decompensated heart failure.
  • Current participation in another structured health promotion, rehabilitation, or exercise program.
  • Disabling stroke, active or advanced cancer, advanced heart failure, severe chronic obstructive pulmonary disease, or another serious medical condition that makes participation unsafe or substantially limits life expectancy.
  • Adjusted Montreal Cognitive Assessment (MoCA) score below the prespecified education-specific thresholds: <14 for illiterate participants, <15 for those with primary-school education, or <21 for those with junior-secondary education or above. One additional point is applied for fewer than 12 years of education, up to a maximum score of 30.
  • Major visual, hearing, speech, or other communication impairment that prevents meaningful participation.
  • Severe uncontrolled psychiatric disorder, major neurocognitive disorder, or end-stage disease that prevents comprehension, cooperation, or safe participation.
  • Any other condition considered medically unsuitable for participation by the treating physician.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: PFIM Intervention Group

Participants in this group will receive the 12-week nurse-led Physical Frailty Intervention Module (PFIM) in addition to usual primary healthcare for hypertension. The intervention includes simplified Baduanjin exercise, nutrition guidance, hypertension self-management education, individualized action planning, self-monitoring, and follow-up support.

The Physical Frailty Intervention Module (PFIM) is a 12-week nurse-led behavioral intervention based on the Health Action Process Approach (HAPA). During Weeks 1-4, participants attend weekly group education sessions on physical frailty, hypertension, nutrition, and exercise safety. During Weeks 5-8, participants attend weekly group sessions and begin home-based simplified Baduanjin practice 2-3 times per week for 15-20 minutes per session. During Weeks 9-12, home practice continues, progressing toward 20-30 minutes per session as tolerated, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11. Standing or seated exercises are assigned according to physical performance and safety assessments. The intervention is provided in addition to usual hypertension care.

Kein Eingriff: Usual Care Control Group

Participants in the control group will receive usual primary healthcare for hypertension, including routine blood pressure monitoring, medication management, general lifestyle advice, and regular follow-up. No structured Physical Frailty Intervention Module (PFIM) will be provided during the 12-week study period.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Physical Frailty Severity Measured by the FRAIL Scale
Zeitfenster: Baseline (Week 0) and Week 12

Physical frailty will be assessed using the five-item FRAIL Scale, covering fatigue, resistance, ambulation, illnesses, and weight loss. Each item is scored 0 or 1, yielding a total score from 0 to 5. Higher scores indicate greater frailty severity. Change will be calculated as the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Physical Performance Measured by the Short Physical Performance Battery (SPPB)
Zeitfenster: Baseline (Week 0) and Week 12

Physical performance will be assessed using the Short Physical Performance Battery (SPPB), comprising balance, 4-meter gait speed, and repeated chair stands. Each component is scored from 0 to 4, yielding a total score from 0 to 12. Higher scores indicate better physical performance. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Nutritional Status Measured by the Mini Nutritional Assessment-Short Form (MNA-SF)
Zeitfenster: Baseline (Week 0) and Week 12

Nutritional status will be assessed using the six-item Mini Nutritional Assessment-Short Form (MNA-SF). Total scores range from 0 to 14, with higher scores indicating better nutritional status. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Health Literacy Measured by the Health Literacy Survey-Short Form 12 (HLS-SF12)
Zeitfenster: Baseline (Week 0) and Week 12

Health literacy will be measured using the 12-item Health Literacy Survey-Short Form (HLS-SF12), covering healthcare, disease prevention, and health promotion. Responses are converted to a standardized index ranging from 0 to 50. Higher scores indicate better health literacy. Change is the Week 12 index minus the baseline index.

Baseline (Week 0) and Week 12
Change in Perceived Social Support Measured by the Perceived Social Support Scale (PSSS)
Zeitfenster: Baseline (Week 0) and Week 12

Perceived social support will be assessed using the 12-item Perceived Social Support Scale (PSSS), covering support from family, friends, and significant others. Each item is rated from 1 to 7, giving a total score from 12 to 84. Higher scores indicate greater perceived social support. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Depressive Symptoms Measured by the 15-Item Geriatric Depression Scale (GDS-15)
Zeitfenster: Baseline (Week 0) and Week 12

Depressive symptoms will be assessed using the 15-item Geriatric Depression Scale (GDS-15). Each item is scored 0 or 1, giving a total score from 0 to 15. Higher scores indicate more severe depressive symptoms. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Quality of Life Measured by the Brief Older People's Quality of Life Questionnaire (OPQOL-brief)
Zeitfenster: Baseline (Week 0) and Week 12

Quality of life will be assessed using the 13-item Brief Older People's Quality of Life Questionnaire (OPQOL-brief). Items are scored on a five-point scale and coded so that higher scores indicate better quality of life. Total scores range from 13 to 65. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

20. November 2026

Primärer Abschluss (Geschätzt)

31. März 2027

Studienabschluss (Geschätzt)

31. März 2027

Studienanmeldedaten

Zuerst eingereicht

12. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • USM/JEPeM/KK/26040291

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant-level data will not be shared outside the study team due to participant privacy and confidentiality considerations.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .